Haystack MRD® Demonstrates Robust Clinical Performance in Specimen Cohort from the Landmark DYNAMIC Colorectal Cancer Trials
Quest Diagnostics' Haystack MRD® test showed 100% specificity and high sensitivity in detecting colorectal cancer recurrence, per a study in The Journal of Molecular Diagnostics. The test, using circulating tumor DNA, outperformed standard biomarkers and validated its performance across 23 solid tumor types. Quest Diagnostics is the provider of the test.
How this was made
The 30-second read
Why it matters
The data shows 100% specificity and high sensitivity, outperforming standard CEA, which may drive adoption and boost Quest's revenue.
Market read
New validation could positively affect Quest's stock and the broader diagnostics sector.
What to watch
Reimbursement policies, insurance coverage, and competition from other ctDNA platforms could limit impact
Background
The press release announces first‑time clinical validation results for Haystack MRD, a liquid biopsy test owned by Quest Diagnostics.
Ticker impact
Quest Diagnostics provides the Haystack MRD test; the article reports new validation showing 100% specificity and high sensitivity, a fresh clinical performance disclosure.
likely upside as market prices in stronger test performance
new data demonstrates superior accuracy over CEA, could increase test adoption and drive revenue growth for Quest Diagnostics
Market effects
strengthens the diagnostics and liquid biopsy sector by showing a highly accurate ctDNA test
supports US diagnostic service providers with potential revenue uplift
could influence adoption of ctDNA MRD testing worldwide
Counterpoint
Skeptics may argue that clinical validation does not guarantee payer reimbursement or market uptake
Key entities
- companyQuest Diagnostics
US‑listed diagnostics provider (ticker DGX) that offers the Haystack MRD test.
- companyHaystack Oncology
Private subsidiary of Quest that developed the MRD assay.
